Efficacy results in the efficacy-evaluable set. Kaplan-Meier curves demonstrating (A) DOR, (B) PFS, and (C) OS are shown. Responses were evaluated by IRC assessment per Lugano 2014 criteria. Kaplan-Meier method was used to calculate median (95% CI) of DOR, PFS, and OS; reverse Kaplan-Meier method was used to calculate median (95% CI) of follow-up. DOR and PFS only included data from TRANSCEND NHL 001. OS included survival data from patients who completed TRANSCEND NHL 001 and enrolled in the subsequent long-term follow-up study.